Calidi Biotherapeutics (CLDI, Financial) has announced a significant advancement in its cancer treatment efforts with the U.S. Food and Drug Administration's clearance of its Investigational New Drug (IND) application for CLD-201. This innovative therapy utilizes an allogeneic stem cell-based immunotherapy approach, targeting the treatment of solid tumors in adults, including breast cancer, head and neck cancer, and soft tissue sarcoma.
The development of CLD-201 represents a breakthrough in the field of virotherapy, as it is the first product to be manufactured using adipose tissue-derived stem cells combined with oncolytic vaccinia virus. This novel approach has the potential to revolutionize cancer treatment options by providing a versatile solution for managing solid tumors.
Calidi's CEO and Chairman, Allan Camaisa, highlighted the importance of this development, emphasizing its potential impact on cancer treatment worldwide. The successful clearance of the IND is attributed to the dedication and hard work of the company's executives and staff. With this clearance, Calidi Biotherapeutics is poised to move forward into clinical development, offering hope for new and effective cancer therapies.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 2 analysts, the average target price for Calidi Biotherapeutics Inc (CLDI, Financial) is $6.25 with a high estimate of $10.00 and a low estimate of $2.50. The average target implies an upside of 1,244.09% from the current price of $0.47. More detailed estimate data can be found on the Calidi Biotherapeutics Inc (CLDI) Forecast page.
Based on the consensus recommendation from 2 brokerage firms, Calidi Biotherapeutics Inc's (CLDI, Financial) average brokerage recommendation is currently 1.0, indicating "Buy" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
